← Back to Search

Monoclonal Antibodies

LY3372689 for Alzheimer's Disease

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months
CDR global score of 0.5 to 1.0 (inclusive), with a memory box score ≥0.5
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 76 to 124 weeks
Awards & highlights

Study Summary

This trial is testing a new drug for Alzheimer's Disease. It is checking to see if the drug is safe, tolerated and effective.

Who is the study for?
This trial is for people with early symptomatic Alzheimer's Disease, who have experienced a gradual memory decline for at least 6 months. Participants should score between 22 to 30 on the MMSE (a cognitive test) and meet specific criteria on a PET brain scan. They need a study partner willing to consent as well.Check my eligibility
What is being tested?
The trial is testing LY3372689, which is being investigated for safety and effectiveness in treating Alzheimer's. Participants will either receive LY3372689 or a placebo without knowing which one they are getting to compare results fairly.See study design
What are the potential side effects?
While the side effects of LY3372689 aren't detailed here, common side effects in trials like this may include allergic reactions, headaches, nausea, or other drug-related issues that will be closely monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My memory has been getting worse for at least 6 months.
Select...
I have mild memory problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 76 to 124 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 76 to 124 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)
Secondary outcome measures
Change From Baseline to End Time Point in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
Change from Baseline to End Time Point in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)
Change from Baseline to End Time Point in Alzheimer's Disease Cooperative Study Instrumental Activities of Daily Living Inventory (ADCS-iADL)
+5 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3372689 Low DoseExperimental Treatment1 Intervention
LY3372689 given orally
Group II: LY3372689 High DoseExperimental Treatment1 Intervention
LY3372689 given orally
Group III: PlaceboPlacebo Group1 Intervention
Placebo given orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3372689
2020
Completed Phase 1
~100

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,610 Previous Clinical Trials
3,200,103 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,342 Previous Clinical Trials
404,426 Total Patients Enrolled

Media Library

Alzheimer's Disease Research Study Groups: LY3372689 High Dose, LY3372689 Low Dose, Placebo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is eligibility for this trial limited to individuals younger than 25 years of age?

"For this clinical trial, only patients aged 60 and above but below 85 are being recruited."

Answered by AI

In what areas are the trials of this experiment currently being conducted?

"At present, 48 clinical trial sites are running this study. Participants have the option of enrolling in Canoga Park, Delray Beach, Dayton and 45 other locales. It is recommended to opt for a nearby location to reduce travel requirements when participating."

Answered by AI

What possible side effects have been observed from taking LY3372689?

"Our team at Power have assessed the safety of LY3372689 as a 2, due to there being some evidence that highlights its protection against harm but no data confirming effectiveness."

Answered by AI

Could I potentially enroll in this trial given my qualifications?

"This experiment seeks 330 individuals between the ages of 60 and 85 suffering from Alzheimer's disease as its primary participants. The applicants must provide evidence of a gradual decrease in memory function over at least 6 months, have a Clinical Dementia Rating global score within 0.5 to 1 (inclusive) with an associated Memory Box rating above 0.5, and possess a Mini Mental State Examination result ranging from 22 to 30 points (inclusive)."

Answered by AI

Is this experiment currently accepting participants?

"According to information hosted on clinicaltrials.gov, this particular medical trial is not currently seeking participants and has been inactive since November 22nd 2022. However, there are 546 other trials actively searching for volunteers at the moment."

Answered by AI

Who else is applying?

What state do they live in?
Other
Pennsylvania
Connecticut
Florida
How old are they?
18 - 65
What site did they apply to?
Institute for Neurodegenerative Disorders
Merritt Island Medical Research, LLC
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
1
0

Why did patients apply to this trial?

Just starting to look for clinical trials.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
2021. "A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05063539.
All > Alzheimers Disease Dallas
~20 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top